Spots Global Cancer Trial Database for alimta
Every month we try and update this database with for alimta cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of TRC102 in Combination With Pemetrexed in Cancer Patients | NCT00692159 | Neoplasm | TRC102 + pemetr... | 18 Years - | Tracon Pharmaceuticals Inc. | |
| Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC) | NCT00487669 | Advanced Non-sm... | paclitaxel poli... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer | NCT00705549 | Non-Small-Cell ... | Gemcitabine Cisplatin Docetaxel Cisplatin Vinorelbine Pemetrexate | 18 Years - | Hellenic Oncology Research Group | |
| A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer | NCT00297089 | Lung Cancer NSCLC Non-Small-Cell ... | ABT-751 pemetrexed placebo | 18 Years - | AbbVie | |
| Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer | NCT01548144 | Advanced Cancer... | Crizotinib (Xal... Pazopanib Pemetrexed | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy | NCT00343720 | Non-Small Cell ... | VELCADE Alimta | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer | NCT00507858 | Head and Neck C... | Pemetrexed Dexamethasone | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma | NCT00712062 | Primary Central... | Pemetrexed | 18 Years - | University of Florida | |
| BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer | NCT01263782 | Lung Cancer | Carboplatin Pemetrexed Bevacizumab Cixutumumab | 18 Years - | M.D. Anderson Cancer Center | |
| ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial. | NCT00051493 | Carcinoma, Non-... | ALIMTA Carboplatin | 18 Years - | Eli Lilly and Company | |
| KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC | NCT04265534 | Non-Small Cell ... Non-squamous No... Non-Squamous No... KEAP1 Gene Muta... NRF2 Gene Mutat... NFE2L2 Gene Mut... | Telaglenastat Carboplatin Che... Pemetrexed Chem... Pembrolizumab I... Placebo Folic acid 400 ... Vitamin B12 100... Dexamethasone 4... | 18 Years - | Calithera Biosciences, Inc | |
| Abraxane and Alimta in Advanced Solid Tumors | NCT00470548 | Breast Cancer Lung Cancer Unspecified Adu... | Abraxane Alimta | 18 Years - | University of California, Davis | |
| Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer | NCT00705549 | Non-Small-Cell ... | Gemcitabine Cisplatin Docetaxel Cisplatin Vinorelbine Pemetrexate | 18 Years - | Hellenic Oncology Research Group | |
| Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer | NCT01548144 | Advanced Cancer... | Crizotinib (Xal... Pazopanib Pemetrexed | 18 Years - | M.D. Anderson Cancer Center | |
| Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel | NCT01192165 | Cancer | Trametinib (GSK... Docetaxel Erlotinib Pemetrexed Carboplatin nab-Paclitaxel Cisplatin | 18 Years - | GlaxoSmithKline | |
| Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed) | NCT00916630 | Central Nervous... | pemetrexed | 18 Years - | Massachusetts General Hospital | |
| Alimta Plus Gemcitabine for Advanced Sarcoma | NCT00860015 | Sarcoma, Soft T... | Alimta Gemcitabine | 18 Years - | Columbia University | |
| A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer | NCT02662634 | Non-small Cell ... | AGS-003-LNG Carboplatin Abraxane Alimta Cisplatin Taxol Radiation Thera... | 19 Years - | GU Research Network, LLC | |
| Alimta Plus Gemcitabine for Advanced Sarcoma | NCT00860015 | Sarcoma, Soft T... | Alimta Gemcitabine | 18 Years - | Columbia University | |
| Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC | NCT01042288 | Non-Small-Cell ... | Carboplatin Pemetrexed Panitumumab | 18 Years - | SCRI Development Innovations, LLC | |
| A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer. | NCT00034619 | Colorectal Canc... | ALIMTA Oxaliplatin | 18 Years - | Eli Lilly and Company | |
| ZD6474(Vandetanib) + Alimta Combo Study | NCT00506051 | Carcinoma Non-Small Cell ... Lung Cancer | ZD6474 (vandeta... pemetrexed ZD6474 (vandeta... | 18 Years - | Sanofi | |
| KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC | NCT04265534 | Non-Small Cell ... Non-squamous No... Non-Squamous No... KEAP1 Gene Muta... NRF2 Gene Mutat... NFE2L2 Gene Mut... | Telaglenastat Carboplatin Che... Pemetrexed Chem... Pembrolizumab I... Placebo Folic acid 400 ... Vitamin B12 100... Dexamethasone 4... | 18 Years - | Calithera Biosciences, Inc | |
| ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer | NCT00034463 | Metastases Cancer | ALIMTA folic acid multi-vitamins | 18 Years - | Eli Lilly and Company | |
| ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer | NCT00034463 | Metastases Cancer | ALIMTA folic acid multi-vitamins | 18 Years - | Eli Lilly and Company | |
| ZD6474(Vandetanib) + Alimta Combo Study | NCT00506051 | Carcinoma Non-Small Cell ... Lung Cancer | ZD6474 (vandeta... pemetrexed ZD6474 (vandeta... | 18 Years - | Sanofi | |
| Pemetrexed Plus Gemcitabine in Renal Cell Cancer | NCT00491075 | Renal Cell Carc... | Pemetrexed Gemcitabine | - | M.D. Anderson Cancer Center | |
| A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer | NCT00297089 | Lung Cancer NSCLC Non-Small-Cell ... | ABT-751 pemetrexed placebo | 18 Years - | AbbVie | |
| A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer. | NCT00034489 | Breast Neoplasm... | pemetrexed gemcitabine | 18 Years - | Eli Lilly and Company | |
| A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas. | NCT00035035 | Pancreatic Neop... Metastases, Neo... | GEMZAR ALIMTA | 18 Years - | Eli Lilly and Company | |
| Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer | NCT00508144 | Lung Cancer | Alimta | 18 Years - | M.D. Anderson Cancer Center | |
| Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer | NCT00508144 | Lung Cancer | Alimta | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | NCT00034593 | Urologic Neopla... | ALIMTA gemcitabine | 18 Years - | Eli Lilly and Company | |
| Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma | NCT00402766 | Mesothelioma | Cisplatin Imatinib Mesyla... Pemetrexed Dexamethasone | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer. | NCT00034489 | Breast Neoplasm... | pemetrexed gemcitabine | 18 Years - | Eli Lilly and Company | |
| Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM) | NCT00604461 | Mesothelioma | Carboplatin, Be... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM) | NCT00604461 | Mesothelioma | Carboplatin, Be... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | NCT00034593 | Urologic Neopla... | ALIMTA gemcitabine | 18 Years - | Eli Lilly and Company | |
| A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer. | NCT00034502 | Colorectal Canc... | ALIMTA irinotecan | 18 Years - | Eli Lilly and Company | |
| ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer. | NCT00051506 | Lung Neoplasms | ALIMTA carboplatin cisplatin | 18 Years - | Eli Lilly and Company | |
| ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial. | NCT00051493 | Carcinoma, Non-... | ALIMTA Carboplatin | 18 Years - | Eli Lilly and Company |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
